A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates

Neurocase
S C RischM S George

Abstract

Cognitive impairment in multiple domains is common in patients with schizophrenia and may be a powerful determinant of poor functional ability and quality of life. We report a double-blind, placebo-controlled, cross-over study of donepezil augmentation in a schizoaffective disorder patient stabilized on olanzapine pharmacotherapy. The patient showed significant improvements in several cognitive measures and increased activation of prefrontal cortex and basal ganglia on functional MRI during the donepezil augmentation. In addition, the donepezil augmentation resulted in a reduction of depressive symptoms and in significant improvements in functional abilities and quality of life. Further studies of donepezil augmentation of neuroleptics in schizophrenia are warranted.

Citations

Jul 13, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Richard S E KeefeRobert Goldman
Nov 26, 2008·The Journal of Clinical Psychiatry·Melissa A CulhaneA Eden Evins
Mar 8, 2007·Expert Review of Neurotherapeutics·Christopher R Bowie, Kushik Jaga
Jul 13, 2006·Expert Review of Neurotherapeutics·Veena Kumari, Michael Cooke
Sep 22, 2005·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Peter FalkaiUNKNOWN WFSBP Task Force on Treatment Guidelines for Schizophrenia
Mar 30, 2017·Inflammopharmacology·Anil KumarDinesh K Dhull
Jul 14, 2005·Journal of Clinical Psychopharmacology·Ingrid AasenTonmoy Sharma
Feb 14, 2012·Journal of Psychopharmacology·Nora S VyasVeena Kumari
Sep 19, 2002·Journal of Psychopharmacology·Andrew K HowardWilliam G Honer
Oct 2, 2003·Journal of Clinical Psychopharmacology·Doron MazehYoram Barak
Jun 30, 2005·Journal of Psychiatric Practice·Robert N Rubey
Apr 20, 2004·Clinical Neuropharmacology·Murray H Rosenthal, Sharon L Bryant
Jan 20, 2012·The Cochrane Database of Systematic Reviews·Jasvinder SinghMahesh B Jayaram
Jul 3, 2004·Journal of Clinical Psychopharmacology·Paul B FitzgeraldJayashri Kulkarni
Jan 16, 2007·Journal of Autism and Developmental Disorders·J Helen YooDean C Williams
Sep 17, 2002·Current Psychiatry Reports·Heather A WishartThomas W McAllister
Jun 27, 2006·European Psychiatry : the Journal of the Association of European Psychiatrists·M PérezZ Lenderová
Aug 5, 2003·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Orly PerlSara Fuchs
Dec 4, 2003·Clinical Neuropharmacology·Alessandro LenziElisabetta Coli

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.